Annual Meeting Presentation

TruScreen Group Ltd

This Presentation
⚫About TruScreen technology
⚫WHO Strategy to eliminate CC, status
⚫Key achievements in financial year
2023
⚫China, our biggest market
⚫Sales growth in financial year 2023
⚫Outlook and goals for financial year
2024
⚫Key takeaways
2

About
TruScreen
technology

4
►
►
►
►
►

5
►
►
►
1
Cervical cancer (who.int)

Status of the WHO strategy, APEC
6
1
APEC Economic Status Report: Cervical Elimination in the APAC region, March 2023

7
European Union:
CE Mark
ISO 13485
Registered with:
✓TGA, Australia
✓MHRA, UK
✓NMPA, China
✓SFDA, Saudi Arabia
✓Roszdravnadzor, Russia
✓COFEPRIS, Mexico
Mexico
10.7 M
119.1 M
13.4 M
Current Markets
Targeting commercial rollout
Markets under review
119.1 M
India
100.1 M
Indonesia
23.1 M
China
119.1 M
Saudi
3.6 M
CE
Europe
6.7 M
Vietnam
8.3 M
* Number of eligible women to undergo cervical cancer screening

8
Effective co-invest model with global distribution
➢
➢
➢
➢
✓
✓
✓
✓
✓
✓

Trusted ClinicalPerformance
9
9

Key
achievements
Sales growth
FY2023

Top Achievements FY23, China
11
•
•
•
•
➢
➢

China
TruScreen’s largest market with growing sales and huge potential
●
●
●
●
●
●

China market, USD M, PBI Market Research 2020
13
*©2020 Precision Business Insights
0.0
500.0
1000.0
1500.0
2000.0
2500.0
3000.0
3500.0
4000.0
2015 (A)2016 (A)2017 (A)2018 (A)2019 (A)2020 (F)2021 (F)2022 (F)2023 (F)2024 (F)2025 (F)2026 (F)
China Cervical Cancer Screening Market Historical and
Forecast, USD Million*
PAP Smear testsHPV testsLBC testsOthers M USD
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
16.0%
CAGR (USD Million), By Test Type,
2015 – 2026*
PAP Smear testsHPV testsLBC testsOthers

China and APAC market, recent growth exceeded
expectations
14
HPV Test Market Revenue (Million USD) and Growth Rate
(2018-2028)
Business Market Insights
June 2023:
➢The Asia Pacific CIN & HR-HPV
treatment market is expected to
grow from US$ 2,738.94 million in
2023 to US$ 3,949.99 million by
2028.
➢It is estimated to grow at a CAGR of
7.6% from 2023 to 2028.

We currently have installed:
•More than 100 devices
•Deployed in hospitals and
clinics in 22 Provinces
China, the status and near future
15
In addition, we have a pipeline of:
•14 Hospital tenders won and awaiting
installation
•26 Hospitals which have approved TruScreen
awaiting tender
•74 Hospitals where we have obtained
OBGYN department acceptance, awaiting
hospital approval
.....These categories get added to each month

China, potential for SUS pull through growth
16
The devices in China
⚫currently have an average pull
through of 85 SUS per device per
month
⚫the potential average pull-through
of SUS exceeds 290 per month
⚫Key accounts reach 500+ SUS pull
through

Vietnam
Focus market with renewed focus on public hospital rollout
●
●
●
●
●
●
●
●
*©2020 Precision Business Insights

●
●
●
●
●
●
●
●
●
FY23,Other Focus Markets

Top achievements FY2023
19
✓
✓
✓
✓
✓
✓

⚫
⚫
KEY FINANCIALS
NZD (m)
FY 21
Actual
FY 22
Actual
FY 23
Actual
Sales1.11.71.7
Total Revenue22.72.2
COGS0.71.31.3
R&D1.31.50.9
EBITDA-2.8-2.7
Write off of Non-Current Assets--4.6-0.05
Amortisation & Depreciation-0.6-0.6-
LOSS FOR YEAR-3.4-7.9-2.4
Net Assets11.33.42.5
Cash5.32.82.2
20

Outlook strategy
and goals
FY2024-2025

22

Our Short Term Goals
23
Maximise
Seize the CSCCP
national guideline
window to grow
sales in China
Expand
Successfully expand
markets in
Zimbabwe, Saudi
Arabia, and Vietnam
Grow
Grow commercial
presence in Africa,
Middle East, Central
and Eastern Europe
Improve
Improve the gross
margin by reducing
COGS

Expansion and adoption of
technology in the screening cervical
cancer guidelines in target markets
Development of technology toward
diagnostics and treatment of
cervical cancer
24
Long Term
Goals

25
Device installations and SUS pull-through
0
50000
100000
150000
200000
250000
300000
0
50
100
150
200
250
300
350
400
450
Mar '19Mar '20Mar '21Mar '22Mar '23Mar '24*Mar '25*
FY2019-FY2023 actual
Installed DevicesSUS Consumption
we are here
FY2024- FY2025 projections*
*This is not a forecast of performance or expected results

Key take-aways
✓Global growth
✓China remains the biggest market
with huge opportunity
✓Technology of the immediate
future
✓Growing and recognised medical
need with strong clinical backing

27
Thank you!

©
www.truscreen.com

29
@TruscreenGroupLtd
@TruscreenGroupLimited

30

31